% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Zitricky:282352,
      author       = {F. Zitricky and A. Försti$^*$ and A. Hemminki and O.
                      Hemminki and K. Hemminki$^*$},
      title        = {{C}onditional {S}urvival in {P}rostate {C}ancer in the
                      {N}ordic {C}ountries {E}lucidates the {T}iming of
                      {I}mprovements.},
      journal      = {Cancers},
      volume       = {15},
      number       = {16},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-01736},
      pages        = {4132},
      year         = {2023},
      note         = {#LA:C020#},
      abstract     = {The incidence of prostate cancer (PC) increased vastly as a
                      result of prostate-specific antigen (PSA) testing. Survival
                      in PC improved in the PSA-testing era, but changes in
                      clinical presentation have hampered the interpretation of
                      the underlying causes.We analyzed survival trends in PC
                      using data from the NORDCAN database for Denmark (DK),
                      Finland (FI), Norway (NO) and Sweden (SE) by analyzing 1-,
                      5- and 10-year relative survival and conditional relative
                      survival over the course of 50 years (1971-2020).In the
                      pre-PSA era, survival improved in FI and SE and improved
                      marginally in NO but not in DK. PSA testing began toward the
                      end of the 1980s; 5-year survival increased by approximately
                      $30\%,$ and 10-year survival improved even more. Conditional
                      survival from years 6 to 10 (5 years) was better than
                      conditional survival from years 2 to 5 (4 years), but by
                      2010, this difference disappeared in countries other than
                      DK. Survival in the first year after diagnosis approached
                      $100\%;$ by year 5, it was $95\%;$ and by year 10, it was
                      $90\%$ in the best countries, NO and SE.In spite of advances
                      in diagnostics and treatment, further attention is required
                      to improve PC survival.},
      keywords     = {PSA screening (Other) / periodic survival (Other) /
                      prognosis (Other) / treatment (Other)},
      cin          = {B062 / HD01 / C020},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37627160},
      pmc          = {pmc:PMC10453103},
      doi          = {10.3390/cancers15164132},
      url          = {https://inrepo02.dkfz.de/record/282352},
}